Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
Keine aktuellen Veranstaltungen.
Vergangene Veranstaltungen (max. 10)
-
SoSe 2021
-
WiSe 2020
-
SoSe 2020
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Comprehensive Assessment of Multikinase Inhibitor Therapy Outcomes in RAIR-(P)DTC and MTC at a Tertiary Referral CenterIn: The Journal of Clinical Endocrinology & Metabolism (JCEM) 2025 , in press
-
Head-to-head comparison of ⁶⁸ Ga-FAPI-46 PET/CT, ¹⁸F-FDG PET/CT, and contrast-enhanced CT for the detection of various tumorsIn: Annals of Nuclear Medicine , Jg. 39 2025, Nr. 3, S. 255 – 265
-
Staging of prostate Cancer with ultra-fast PSMA-PET scans enhanced by AIIn: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 52 2025, Nr. 5, S. 1658 – 1670DOI (Open Access)
-
Biodistribution and radiation dosimetry of ¹²⁴I-mIBG in adult patients with neural crest tumours and extrapolation to paediatric modelsIn: EJNMMI Physics , Jg. 11 2024, Nr. 1, 3DOI, Online Volltext (Open Access)
-
Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRTIn: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 51 2024, Nr. 3, S. 841 – 851DOI (Open Access)
-
Dose-Response Relationship in Patients with Liver Metastases from Neuroendocrine Neoplasms Undergoing Radioembolization with ⁹⁰Y Glass MicrospheresIn: Journal of Nuclear Medicine (JNM) , Jg. 65 2024, Nr. 8, S. 1175 – 1180
-
Prognostic Implications of ⁶⁸Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid TumorsIn: Journal of Nuclear Medicine (JNM) , Jg. 65 2024, Nr. 7, S. 1027 – 1034
-
Prostate-specific Membrane Antigen Positron Emission Tomography–detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer : An International Multicenter Retrospective StudyIn: European Urology , Jg. 85 2024, Nr. 6, S. 511 – 516DOI (Open Access)
-
RECIP 1.0 Predicts Progression-Free Survival After [¹⁷⁷Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate CancerIn: Journal of Nuclear Medicine (JNM) , Jg. 65 2024, Nr. 6, S. 917 – 922
-
Thyroglobulin measurement is the most powerful outcome predictor in differentiated thyroid cancer : a decision tree analysis in a European multicenter seriesIn: Clinical Chemistry and Laboratory Medicine , Jg. 62 2024, Nr. 11, S. 2307 – 2315
-
68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment : An International Multicenter Prospective StudyIn: Journal of Nuclear Medicine (JNM) , Jg. 64 2023, Nr. 7, S. 1043 – 1048DOI (Open Access)
-
Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma : Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/BevacizumabIn: Cancers , Jg. 15 2023, Nr. 17, 4274DOI (Open Access)
-
Correlation of the apparent diffusion coefficient with the standardized uptake value in meningioma of the skull plane using [68]Ga-DOTATOC PET/MRIIn: Nuclear Medicine Communications , Jg. 44 2023, Nr. 12, S. 1106 – 1113
-
Efficacy and Safety of¹²⁴I-MIBG Dosimetry-Guided High-Activity¹³¹I-MIBG Therapy of Advanced Pheochromocytoma or NeuroblastomaIn: Journal of Nuclear Medicine (JNM) , Jg. 64 2023, Nr. 6, S. 885 – 891DOI (Open Access)
-
Evaluation of [⁶⁸Ga]-DOTATOC PET/MRI in Patients with Meningioma of the Subcranial and Intraorbital SpaceIn: Journal of Nuclear Medicine (JNM) , Jg. 64 2023, Nr. 8, S. 1185 – 1190DOI (Open Access)
-
Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid CarcinomaIn: Journal of Nuclear Medicine (JNM) , Jg. 64 2023, Nr. 12, S. 1865 – 1868DOI (Open Access)
-
PET/CT-identified atrial hypermetabolism is an index of atrial inflammation in patients with atrial fibrillationIn: Journal of Nuclear Cardiology , Jg. 30 2023, Nr. 5, S. 1761 – 1772.
-
PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [¹⁷⁷Lu]PSMA Radioligand Therapy : An International Multicenter Retrospective StudyIn: Journal of Nuclear Medicine (JNM) , Jg. 64 2023, Nr. 7, S. 1024 – 1029DOI (Open Access)
-
PSMA-Directed Imaging and Therapy of Salivary Gland Tumors : A Single-Center Retrospective StudyIn: Journal of Nuclear Medicine (JNM) , Jg. 64 2023, Nr. 3, S. 372 – 378DOI (Open Access)
-
Postoperative thyroglobulin as a yard-stick for radioiodine therapy : decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancerIn: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 50 2023, Nr. 9, S. 2767 – 2774DOI (Open Access)
-
Predictive value of highly sensitive basal versus stimulated thyroglobulin measurement in long-term follow-up of thyroid cancerIn: Endocrine Connections , Jg. 12 2023, Nr. 2, e220312DOI, Online Volltext (Open Access)
-
Prognostic Implications of PET-Derived Tumor Volume and Uptake in Patients with Neuroendocrine TumorsIn: Cancers , Jg. 15 2023, Nr. 14, 3581DOI (Open Access)
-
Quantification performance of silicon photomultiplier-based PET for small ¹⁸F-, ⁶⁸Ga- and ¹²⁴I-avid lesions in the context of radionuclide therapy planningIn: Physica Medica: European Journal of Medical Physics , Jg. 114 2023, 103149DOI (Open Access)
-
Quantitative ⁹⁹mTc-DPD-SPECT/CT assessment of cardiac amyloidosisIn: Journal of Nuclear Cardiology , Jg. 30 2023, Nr. 1, S. 101 – 111DOI (Open Access)
-
Radioiodine Ablation of Thyroid Remnants in Patients with Graves' OrbitopathyIn: Journal of Nuclear Medicine (JNM) , Jg. 64 2023, Nr. 4, S. 561 – 566DOI (Open Access)
-
Real-Life Experience in the Treatment of Intrahepatic Cholangiocarcinoma by ⁹⁰Y Radioembolization : A Multicenter Retrospective StudyIn: Journal of Nuclear Medicine (JNM) , Jg. 64 2023, Nr. 4, S. 529 – 535DOI (Open Access)
-
Reduction of emission time for [68Ga]Ga-PSMA PET/CT using the digital biograph vision : A phantom studyIn: The Quarterly Journal of Nuclear Medicine and Molecular Imaging , Jg. 67 2023, Nr. 1, S. 57 – 68
-
Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate CancerIn: Radiology , Jg. 308 2023, Nr. 1, e222148DOI (Open Access)
-
SUVmₐₓ Above 20 in ¹⁸F-FDG PET/CT at Initial Diagnostic Workup Associates with Favorable Survival in Patients with Cancer of Unknown PrimaryIn: Journal of Nuclear Medicine (JNM) , Jg. 64 2023, Nr. 8, S. 1191 – 1194DOI (Open Access)
-
Update on Calcitonin Screening for Medullary Thyroid Carcinoma and the Results of a Retrospective Analysis of 12,984 Patients with Thyroid NodulesIn: Cancers , Jg. 15 2023, Nr. 8, 2333DOI (Open Access)
-
Visualization of fibroblast activation using ⁶⁸Ga-FAPI PET/CT after pulmonary vein isolation with pulsed field compared with cryoballoon ablationIn: Journal of Nuclear Cardiology , Jg. 30 2023, Nr. 5, S. 2018 – 2028DOI (Open Access)
-
Voxel-Based Dosimetry Predicts Hepatotoxicity in Hepatocellular Carcinoma Patients Undergoing Radioembolization with ⁹⁰Y Glass MicrospheresIn: Journal of Nuclear Medicine (JNM) , Jg. 64 2023, Nr. 7, S. 1102 – 1108DOI (Open Access)
-
Artificial intelligence guided enhancement of digital PET : Scans as fast as CT?In: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 49 2022, Nr. 13, S. 4503 – 4515DOI (Open Access)
-
Diagnostic Performance of ¹²⁴I-Metaiodobenzylguanidine PET/CT in Patients with PheochromocytomaIn: Journal of Nuclear Medicine (JNM) , Jg. 63 2022, Nr. 6, S. 869 – 874DOI (Open Access)
-
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compoundsIn: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 49 2022, Nr. 5, S. 1682 – 1699DOI (Open Access)
-
Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI) : A Single-Center Prospective Two-Arm StudyIn: Clinical Cancer Research , Jg. 28 2022, Nr. 19, S. 4194 – 4202DOI (Open Access)
-
Initial Clinical Experience with ⁹⁰Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors : A Case Series of 9 PatientsIn: Journal of Nuclear Medicine (JNM) , Jg. 63 2022, Nr. 5, S. 727 – 734DOI (Open Access)
-
Intra-Individual Comparison of 124I-PET/CT and 124I-PET/MR Hybrid Imaging of Patients with Resected Differentiated Thyroid Carcinoma : Aspects of Attenuation CorrectionIn: Cancers , Jg. 14 2022, Nr. 13, 3040DOI, Online Volltext (Open Access)
-
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT : comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteriaIn: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 49 2022, Nr. 12, S. 4271 – 4281DOI (Open Access)
-
Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0) : An International Multicenter StudyIn: Journal of Nuclear Medicine (JNM) , Jg. 63 2022, Nr. 11, S. 1651 – 1658DOI (Open Access)
-
Phantom-based acquisition time and image reconstruction parameter optimisation for oncologic FDG PET/CT examinations using a digital systemIn: BMC Cancer , Jg. 22 2022, Nr. 1, 899DOI, Online Volltext (Open Access)
-
Pitfalls and Common Findings in ⁶⁸Ga-FAPI PET : A Pictorial AnalysisIn: Journal of Nuclear Medicine (JNM) , Jg. 63 2022, Nr. 6, S. 890 – 896DOI (Open Access)
-
Prediction of left lobe hypertrophy after right lobe radioembolization of the liver using a clinical data model with external validationIn: Scientific Reports , Jg. 12 2022, Nr. 1, 20718DOI, Online Volltext (Open Access)
-
Radiation dose aspects and establishment of diagnostic reference levels for 90Y radioembolisation during angiographic procedureIn: Journal of Radiological Protection , Jg. 42 2022, Nr. 3, 031518DOI (Open Access)
-
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesIn: Clinical Cancer Research , Jg. 28 2022, Nr. 19, S. 4346 – 4353DOI (Open Access)
-
Tumor Sink Effect in ⁶⁸Ga-PSMA-11 PET : Myth or Reality?In: Journal of Nuclear Medicine (JNM) , Jg. 63 2022, Nr. 2, S. 226 – 232DOI (Open Access)
-
Visualization of thermal damage using ⁶⁸ Ga-FAPI-PET/CT after pulmonary vein isolationIn: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 49 2022, S. 1553 – 1559DOI (Open Access)
-
⁹⁰Y Radioembolization in the Treatment of Neuroendocrine Neoplasms : Results of an International Multicenter Retrospective StudyIn: Journal of Nuclear Medicine (JNM) , Jg. 63 2022, Nr. 5, S. 679 – 685DOI (Open Access)
-
18 F-FDG-PET/MRI in patients with Graves’ orbitopathyIn: Graefes Archive for Clinical and Experimental Ophthalmology , Jg. 259 2021, Nr. 10, S. 3107 – 3117DOI (Open Access)
-
Analysis of risk factors and prognosis in differentiated thyroid cancer with focus on minimal extrathyroidal extensionIn: BMC Endocrine Disorders , Jg. 21 2021, Nr. 1, 161DOI, Online Volltext (Open Access)
-
Artificial Intelligence and Machine Learning in Nuclear Medicine : Future PerspectivesIn: Seminars in Nuclear Medicine , Jg. 51 2021, Nr. 2, S. 170 – 177
-
Comparing lesion detection efficacy and image quality across different PET system generations to optimize the iodine-124 PET protocol for recurrent thyroid cancerIn: EJNMMI Physics , Jg. 8 2021, Nr. 1, 14DOI, Online Volltext (Open Access)
-
Diagnostic accuracy of routine calcitonin measurement for the detection of medullary thyroid carcinoma in the management of patients with nodular thyroid disease : A meta-analysisIn: Endocrine Connections , Jg. 10 2021, Nr. 3, S. 358 – 370DOI (Open Access)
-
Equivalent tumor detection for early and late FAPI-46 PET acquisitionIn: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 48 2021, Nr. 10, S. 3221 – 3227DOI (Open Access)
-
Evaluation of [⁶⁸Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph visionIn: EJNMMI Research , Jg. 11 2021, Nr. 1, S. 21DOI, Online Volltext (Open Access)
-
Evaluation of a new automated assay for high-sensitivity thyroglobulin measurement and comparison with two established high-sensitivity thyroglobulin assaysIn: Practical Laboratory Medicine , Jg. 26 2021, e00250DOI, Online Volltext (Open Access)
-
Evaluation of ¹⁸F-FDG PET/CT images acquired with a reduced scan time duration in lymphoma patients using the digital biograph visionIn: BMC Cancer , Jg. 21 2021, Nr. 1, 62DOI, Online Volltext (Open Access)
-
Fabry Cardiomyopathy : Current Treatment and Future OptionsIn: Journal of Clinical Medicine (JCM) , Jg. 10 2021, Nr. 14, 3026DOI (Open Access)
-
Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging : A Multicenter Retrospective StudyIn: Journal of Nuclear Medicine (JNM) , Jg. 62 2021, Nr. 5, S. 675 – 678DOI (Open Access)
-
Just another “Clever Hans”? : Neural networks and FDG PET-CT to predict the outcome of patients with breast cancerIn: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 48 2021, Nr. 10, S. 3141 – 3150DOI (Open Access)
-
Machine learning-based differentiation between multiple sclerosis and glioma WHO II°-IV° using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomographyIn: Journal of Neuro-Oncology , Jg. 152 2021, S. 325 – 332
-
Nomograms to predict outcomes after ¹⁷⁷Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer : An international, multicentre, retrospective studyIn: The Lancet Oncology , Jg. 22 2021, Nr. 8, S. 1115 – 1125DOI (Open Access)
-
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysisIn: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 48 2021, Nr. 4, S. 1200 – 1210DOI (Open Access)
-
PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of diseaseIn: Journal of Nuclear Medicine (JNM) , Jg. 62 2021, Nr. 12, S. 1747 – 1750DOI (Open Access)
-
Predictive Factors for RAI-Refractory Disease and Short Overall Survival in PDTCIn: Cancers , Jg. 13 2021, Nr. 7, S. 1728DOI, Online Volltext (Open Access)
-
Prostate-specific Membrane Antigen–based Imaging of Castration-resistant Prostate CancerIn: European Urology Focus , Jg. 7 2021, Nr. 2, S. 279 – 287
-
Silicon-photomultiplier-based PET/CT reduces the minimum detectable activity of iodine-124In: Scientific Reports , Jg. 11 2021, Nr. 1, 17477DOI, Online Volltext (Open Access)
-
Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapyIn: Theranostics , Jg. 11 2021, Nr. 17, S. 8143 – 8151DOI (Open Access)
-
[⁶⁸Ga]Ga-PSMA-11 PET/CT improves tumor detection and impacts management in patients with hepatocellular carcinomaIn: Journal of Nuclear Medicine (JNM) , Jg. 62 2021, Nr. 9, S. 1235 – 1241DOI (Open Access)
-
Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective StudyIn: The Journal of Urology , Jg. 202 2019, Nr. 6, S. 1174 – 1181
-
Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancerIn: Clinical Cancer Research , Jg. 25 2019, Nr. 24, S. 7448 – 7454DOI (Open Access)
-
The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancerIn: The Quarterly Journal of Nuclear Medicine and Molecular Imaging , Jg. 63 2019, Nr. 3, S. 235 – 252
-
Assessment of Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-Resistant Prostate Cancer
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 50 2023, Nr. 1 supplement, S. S544 – S545 -
Head-to-head comparison of68Ga-FAPI46 PET/CT,18F-FDG PET/CT, and contrast- enhanced CT in patient with various solid tumors
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 50 2023, Nr. 1 supplement, S. 166 – S167 -
Occurence of hematotoxic side effects during 90Y-FAPI-46 radioligand therapy (RLT) in patients with advanced metastatic tumor diseases
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 50 2023, Nr. 1 supplement, S. S671DOI (Open Access) -
Practical RECIP : Visual assessment of Response Evaluation Criteria In PSMA-PET/CT in metastatic castration-resistant prostate cancer
55th Annual Conference of the Society-of-Nuclear-Medicine (SNMICON); NOV 16-19, 2023; Jodhpur, India,In: Journal of Nuclear Medicine (JNM) , Jg. 64 2023, Nr. Suppl. 1, P1619 -
Prognostic value of the post-treatment 177Lu-DOTATOC scintigraphy in NET patients undergoing PRRT
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023, Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 50 2023, Nr. 1 supplement, S. S134 -
Changes in Tumor-Blood Ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 49 2022, Nr. Supplement 1, S. S80DOI (Open Access) -
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT : Comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 49 2022, Nr. Supplement 1, S. S267DOI (Open Access) -
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0) : An international multicenter study
EAU22: 37th Annual EAU Congress, 01.-04.07.2022, Amsterdam,In: European Urology , Jg. 81 2022, Nr. Supplement 1: Abstracts EAU22 - 37th Annual EAU Congress, S. S794 – S795 -
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0) : an international multicenter study
2022 ASCO Genitourinary Cancers Symposium, 17.-19.02.2022, San Fransisco,In: Journal of Nuclear Medicine (JNM) , Jg. 40 2022, Nr. 6, Supplement: 2022 ASCO Genitourinary Cancers Symposium, jnumed.121.263072DOI (Open Access) -
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0) : an international multicenter study
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022 Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 49 2022, Nr. Supplement 1, S. S269DOI (Open Access) -
PSMA-directed imaging and therapy of salivary gland tumors : a single-center retrospective study
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 49 2022, Nr. Supplement 1, S. S229DOI (Open Access) -
Radiation Exposure of I-124-MIBG Imaging in Adult Patients with Neuroendocrine Tumours
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 49 2022, Nr. Supplement 1, S. S36 – S37DOI (Open Access) -
Safety and efficacy of [90Y]Y-FAPI-46 radioligand therapy in patients with advanced sarcomas and other cancer entities
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology , Jg. 33 2022, Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S1231 – S1232DOI (Open Access) -
A novel theranostic approach for sarcoma : Insights on diagnostic and therapeutic use of FAP-radioligands
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment , Jg. 44 2021, Nr. Supplement 2, S. 11 – 12DOI (Open Access) -
Development of a novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP) : An international multicenter study
EANM‘21 ; 34th Annual Congress of the European Association of Nuclear Medicine ; October 20-23, 2021, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 48 2021, Nr. Suppl. 1, S. S311 – S312DOI (Open Access) -
Efficacy and safety of 124-I-MIBG guided high activity 131-I-MIBG therapy of metastatic pheochromocytoma and neuroblastomaIn: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 48 2021, Nr. Suppl. 1, S. 290 – S291
-
Increased FDG uptake in AF individuals suggesting atrial inflammation visualized by FDG PET/CT with glucose uptake suppression protocolsIn: European Heart Journal , Jg. 42 2021, Nr. Supplement_1, ehab724.0324DOI (Open Access)
-
Initial clinical experience with [Y-90]Y-FAPI-46 radioligand therapy for advanced stage solid tumors
Annual Congress of the European Association of Nuclear Medicine, October 20-23, 2021, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 48 2021, Nr. Suppl. 1, S. S290DOI (Open Access) -
Interim PSMA PET/CT for response evaluation during LuPSMA treatment in mCRPC (INTERIM PET) : An explorative, multicenter studyIn: Journal of Clinical Oncology (JCO) , Jg. 39 2021, Nr. 15_Suppl, S. 5066 – 5066DOI (Open Access)
-
Nomograms to predict outcome after LuPSMA radionuclide therapy in men with metastatic castration-resistant prostate cancer : An international multicenter retrospective studyIn: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 48 2021, Nr. Suppl. 1, S. 63 – S64
-
Efficacy and safety of 177Lu-PSMA radionuclide treatment in patients with diffuse bone marrow involvement : a multicenter retrospective study
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 47 2020, Nr. Supplement 1, S. S491DOI (Open Access) -
Efficacy and safety of Lu ¹⁷⁷-PSMA radionuclide treatment in patients with diffuse bone marrow involvement : A multicenter retrospective study
2020 ASCO Annual Meeting, May 29-31, 2020, Chicago, Ill., USA,In: Journal of Clinical Oncology (JCO) , Jg. 38 2020, Nr. Suppl. 15, e17543DOI (Open Access) -
Evaluation of 68Ga-PSMA PET/CT Images Acquired with a Reduced Scan Time Duration in Prostate Cancer Patients using a Digital PET/CT Scanner
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 47 2020, Nr. Supplement 1, S. S27DOI (Open Access) -
PSMA-PET identifies PCWG3 target populations with high concordance however superior reproducibility when compared to conventional imaging
Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), July 11-14, 2020, Virtual,In: Journal of Nuclear Medicine (JNM) , Jg. 61 2020, Nr. Suppl. 1, 1260 -
Prognostic markers for overall survival and outcome to LuPSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer
2020 ASCO Annual Meeting, May 29-31, 2020, Chicago, Ill., USA,In: Journal of Clinical Oncology (JCO) , Jg. 38 2020, Nr. 15, Suppl., 5548DOI (Open Access) -
Prognostic markers for overall survival and outcome to LuPSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 47 2020, Nr. Supplement 1, S. S487DOI (Open Access) -
PET imaging in thyroid cancerIn: Nuclear Medicine and Molecular Imaging: Volume 3: PET studies / Signore, Alberto; Macapinlac, Homer; Treglia, Giorgio (Hrsg.) 2022, S. 99 – 104
-
68Ga-FAPI-46 PET/CT for cancer imaging : Results of a single-center, prospective, interventional, single-arm clinical trial
2025 ASCO Genitourinary Cancers Symposium, February 13-15, 2025, San Francisco, CA, USA,In: Journal of Clinical Oncology (JCO) , Jg. 43 2025, Nr. 5, Supplement, 457 -
Emission time optimisation for [68Ga]Ga-PSMA-11 with a SiPM PET/CT based on phantom measurements
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 47 2020, Nr. Supplement 1, S. S256DOI (Open Access) -
Emission time reduction for 2-[18F]FDG examinations in lymphoma patients with a PET/CT with SiPM - a feasibility phantom study
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 47 2020, Nr. Supplement 1, S. S257 – S258DOI (Open Access)